FDA approves two Novo Nordisk insulin pens

PLAINSBORO, N.J. — The Food and Drug Administration has approved two new insulin pens made by Novo Nordisk, the Danish drug maker said Friday.

Novo Nordisk announced the FDA approval of Novolog FlexTouch (insulin aspart [rDNA origin]) and Levemir FlexTouch (insulin detemir [rDNA origin]).

FlexTouch is a new profiled insulin delivery system that allows patients to administer insulin by pressing a low-dose-force button. In traditional insulin pens, a push button extends when a dose is dialed, which can present challenges for a patient at higher doses, the company said.